DxS has expanded its licence with Genzyme Genetics for epidermal growth factor receptor (EGFR) to include the United States and Canada.
The licence grants DxS the rights to develop and commercialise diagnostic and research products that detect mutations in the EGFR gene for non-small cell lung cancer.
